Langerhans cell histiocytosis: Difference between revisions

Jump to navigation Jump to search
m (Robot: Changing Category:Disease state to Category:Disease)
(Mahshid)
 
(27 intermediate revisions by 6 users not shown)
Line 1: Line 1:
{|style="padding:0.3em; float:right; margin-left:15px; border:1px solid #A3B1BF; background:#f5faff; text-align:center; font-size:90%; line-height:1.5em;"
__NOTOC__
!style="background:#eed; padding:0.3em; text-align:center;"|Alternative names
'''For patient information, click [[Langerhans cell histiocytosis (patient information)|here]]'''
|-
{{Langerhans cell histiocytosis}}
|Histiocytosis X
{{CMG}};{{AE}}
Histiocytosis X syndrome
|-
|style="padding:0.1em; background-color:#eed;text-align:left;"|'''Subordinate terms'''
|-
|Hand-Schüller-Christian disease
Letterer-Siwe disease
<br />Histiocytosis X, unspecified
<br />Eosinophilic granulomatosis
<br />Langerhans cell granulomatosis
<br />Langerhans cell histiocytosis -Hashimoto-Pritzker type
<br />Langerhans cell histiocytosis of lung
<br />Langerhans cell histiocytosis, disseminated (clinical)
<br />Langerhans cell histiocytosis, unifocal (clinical)
|}


{{DiseaseDisorder infobox |
{{SK}} Histiocytosis X; Histiocytosis X syndrome; Hand-Schüller-Christian disease; Letterer-Siwe disease; Eosinophilic granulomatosis unspecified; Langerhans cell granulomatosis; Langerhans cell histiocytosis-Hashimoto-Pritzker type; Langerhans cell histiocytosis, disseminated (clinical); Langerhans cell histiocytosis, unifocal (clinical); Langerhans cell histiocytosis of the lung; Non-lipid reticuloendotheliosis; Eosinophilic granuoloma; Pulmonary histiocytosis X; Pulmonary Langerhans cell granulomatosis
  Name          = Langerhans cell histiocytosis |
  Image          = |
  Caption        = |
  ICD10          = {{ICD10|D|76|0|d|70}} |
  ICD9          = {{ICD9|202.5}}, {{ICD9|277.89}} |
  ICDO          = {{ICDO|9752|3}},{{ICDO|9751|1}}  |
  OMIM          = 604856 |
  DiseasesDB    = 5906 |
  MedlinePlus    = |
  MeshID        = D006646 |
}}
{{SI}}
{{CMG}}


{{Editor Help}}
==[[Langerhans cell histiocytosis overview|Overview]]==


==Overview==
==[[Langerhans cell histiocytosis historical perspective|Historical Perspective]]==
'''Langerhans Cell Histiocytosis (LCH)''' is a rare [[disease]] involving clonal proliferation of [[langerhans cell]]s, abnormal [[cell (biology)|cell]]s deriving from [[bone  marrow]] and capable of migrating from skin to [[lymph nodes]].  Clinically, its manifestations range from isolated bone lesions to [[systemic disease|multisystemic disease]].


The disease is part of a group of clinical  syndromes called [[Histiocytosis|histiocytoses]], which are characterized by an abnormal proliferation of [[histiocyte]]s (an archaic term for dendritic cells and macrophages). These diseases are related to other forms of abnormal proliferation of white blood cells, such as [[leukemia]]s and [[lymphomas]].
==[[Langerhans cell histiocytosis pathophysiology|Pathophysiology]]==


Langerhans Cell Histiocytosis  used to be called histiocytosis X, until it was renamed in 1985 by the Histiocyte society<ref>{{cite journal |author= |title=Histiocytosis syndromes in children. Writing Group of the Histiocyte Society |journal=Lancet |volume=1 |issue=8526 |pages=208-9 |year=1987 |pmid=2880029}}</ref> 
==[[Langerhans cell histiocytosis causes|Causes]]==


==Pathophysiology==
==[[Langerhans cell histiocytosis differential diagnosis|Differentiating Langerhans cell histiocytosis from other Diseases]]==
The disease spectrum results from [[Clone (genetics)|clonal]] accumulation and [[proliferation]] of cells resembling the epidermal [[dendritic cells]] called [[langerhans cell]]s, hence sometimes called '''dendritic cell histiocytosis'''. These cells in combination with [[lymphocytes]], [[eosinophils]] and normal [[histiocytes]] form typical LCH lesion that can be found in almost any [[Organ (anatomy)|organ]]<ref>{{cite journal |author=Makras P, Papadogias D, Kontogeorgos G, Piaditis G, Kaltsas G |title=Spontaneous gonadotrophin deficiency recovery in an adult patient with Langerhans cell histiocytosis (LCH) |journal=Pituitary |volume=8 |issue=2 |pages=169-74 |year=2005 |pmid=16379033}}</ref>.


There are three types of histiocytoses<ref name="robbins"/>1. malignant (true histiocytic lymphomas)
==[[Langerhans cell histiocytosis epidemiology and demographics|Epidemiology and Demographics]]==
2. "reactive" (benign histiocytoses)
3. Langerhans Cell Histiocytosis


"Reactive" in this context indicates that the abnormality may be due to a physiological reaction to infection. For example [[leukocytosis]] (proliferation of white blood cells) is a normal reaction to infection, and "histiocytes" are developmentally related to white blood cells (see article [[hematopoiesis]]).
==[[Langerhans cell histiocytosis risk factors|Risk Factors]]==


Langerhans Cell Histiocytoses are traditionally divided into three groups:<ref name="robbins"> {{cite book |author=Cotran, Ramzi S.; Kumar, Vinay; Abbas, Abul K.; Fausto, Nelson; Robbins, Stanley L. |title=Robbins and Cotran pathologic basis of disease |publisher=Elsevier Saunders |location=St. Louis, Mo |year=2005 |pages=701- |isbn=0-8089-2302-1 |oclc= |doi=}}</ref>
==[[Langerhans cell histiocytosis screening|Screening]]==
* '''Unifocal''' (aka "Eosinophilic granuloma"): a slowly progressing disease, characterized by an expanding proliferation of Langerhans cells in various bones, skin, lungs or stomach.
* '''Multifocal unisystem''': characterized by fever and diffuse eruptions, usually on the scalp and in the ear canals, as well as bone lesions. Mostly seen in children. In 50% of cases the stalk of the [[pituitary]] gland is involved, leading to [[diabetes insipidus]]. The triad of [[diabetes insipidus]], [[proptosis]], and lytic bone lesions is known as ''Hand-Schuller-Christian triad''
*'''Multifocal multisystem''' ([[Letterer-Siwe disease]]): a rapidly progressing disease where Langerhans cells proliferate in many tissues. It is mostly seen in children under age 2, and the prognosis is poor: even with aggressive chemotherapy, the 5-year survival is only 50%.


Pulmonary Langerhans cell histiocytosis (PLCH) is a smoking-related interstitial lung disease, used to be considered a benign condition in adults, long term complications like [[pulmonary hypertension]] is becoming increasingly recognized.
==[[Langerhans cell histiocytosis natural history|Natural History, Complications and Prognosis]]==
 
== Prevalence ==
LCH histiocytosis usually affects children of between 1 and 15 years old and peak incidence is between age 5 and 10.  Among children under the age of 10, yearly incidence is thought to be 1 in 200,000<ref>{{cite web |url=http://www.nlm.nih.gov/medlineplus/ency/article/000068.htm |title=MedlinePlus Medical Encyclopedia: Histiocytosis |accessdate=2007-05-10 |format= |work=}}</ref>; and in adults even more rare, in about 1 in 560,000.<ref>{{cite web|url=http://www.histiocytosis.ca/facts.html | title=Histiocytosis Association of Canada | accessdate=2007-05-16|format= |work=}}</ref> It has been reported in elderly but is vanishingly rare<ref>{{cite journal |author=Gerlach B, Stein A, Fischer R, Wozel G, Dittert D, Richter G |title=[Langerhans cell histiocytosis in the elderly] |language=German |journal=Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete |volume=49 |issue=1 |pages=23-30 |year=1998 |pmid=9522189}}</ref>. commoner in white race and boys are effected twice as often as girls.
 
LCH is usually sporadic and non-[[hereditary]] condition but familial clustering has been noted in limited number of cases. Hashimoto-Pritzker disease, a variant of Hand-Schüller-Christian disease, is a congenital self-healing form<ref>{{cite journal |author=Kapur P, Erickson C, Rakheja D, Carder K, Hoang M |title=Congenital self-healing reticulohistiocytosis (Hashimoto-Pritzker disease): ten-year experience at Dallas Children's Medical Center |journal=J. Am. Acad. Dermatol. |volume=56 |issue=2 |pages=290-4 |year=2007 |pmid=17224372}}</ref>.
 
==Clinical Feature==
[[Image:LCH1.jpg|left|thumb|LCH infiltrating peri-orbital tissue(arrowed)]]
Features can be non-specific from generalized [[inflammatory]] response e.g fever, [[lethargy]], weight loss or can be due to specific organ involvement.
 
[[Organs]] involved:
*Bone: Most frequent in both unifocal and disseminated disease presenting as painful swelling. Skull, long bone of upper extremity, flat bones are affected in descending order. Infiltration in hands and feet is unusual. Osteolytic lesions can lead to pathological fractures.
*Skin: Commonly present as rash which varies between scaly erythematous lesions to red papules pronounced in [[Intertrigo|intertriginous]] areas. Up to 80% of LS would have extensive eruptions on the scalp.
*Bone marrow : Pancytopenia with super added infection usually implies poor prognosis. Anemia can be due to number of factors and not necessarily implies bone marrow infiltration.
*Lymph node: cervical commonest. enlargement of the liver in 20%, spleen in 30% and lymph nodes in 50% of HSC.<ref>{{cite web |url=http://www.patient.co.uk/showdoc/40002781/#notes |title=Langerhans cell histiocytosis - Patient UK |accessdate=2007-05-10 |format= |work=}}</ref>
*[[Endocrine]] glands:[[Hypothalamic-pituitary-adrenal axis|Hypothalamic pituitary axis]]  commonly involved. Diabetes insipidus most common. [[Anterior pituitary]] [[hormone]] deficiency is usually permanent.
*Lungs:
*Less frequently GIT, CNS.


==Diagnosis==
==Diagnosis==
[[Image:Eosinophilic granuloma - X-ray of the skull.jpg|left|thumb|Xray of skull showing Eosinophilic Granuloma(arrow)]]
[[Langerhans cell histiocytosis history and symptoms|History amd Symptoms]] | [[Langerhans cell histiocytosis physical examination|Physical Examination]] | [[Langerhans cell histiocytosis laboratory tests|Laboratory Findings]] | [[Langerhans cell histiocytosis electrocardiogram|Electrocardiogram]] | [[Langerhans cell histiocytosis chest x ray|Chest X Ray]] | [[Langerhans cell histiocytosis CT|CT]] | [[Langerhans cell histiocytosis MRI|MRI]] | [[Langerhans cell histiocytosis echocardiography or ultrasound|Echocardiography or Ultrasound]] | [[Langerhans cell histiocytosis other imaging findings|Other Imaging Findings]] | [[Langerhans cell histiocytosis other diagnostic studies|Other Diagnostic Studies]]
Diagnosis is confirmed [[histologically]] by [[tissue]] [[biopsy]].
<br />Haemotoxilin-eosin stain of biopsy slide will show features of Langerhans cell e.g. distinct cell margin, pink granular [[cytoplasm]]. Presence of [[Birbeck granules]] on [[electron microscopy]] and [[immuno-cytochemistry|immuno-cytochemical]] features e. g. [[CD1]] positivity are more specific.
<br />Initially routine blood tests e.g. full blood count, liver function test, U&Es, bone profile are done to determine disease extent and rule out other causes.
<br />Radiology will show osteolytic bone lesions and damage to the lung. Latter may be evident in CXR with micronodular and [[interstitial]] infiltrate in the mid and lower zone of lung, with sparing of the [[Costophrenic angle]] or [[honeycomb]] appearance in older lesions. [[MRI]] and [[CT]] may show infiltration in [[sella turcica]].
<br />Assessment of [[endocrine]] function and bonemarrow biopsy are also performed when indicated.


==Treatment==
==Treatment==
Treatment is guided by extent of disease.
[[Langerhans cell histiocytosis medical therapy|Medical Therapy]] | [[Langerhans cell histiocytosis surgery|Surgery]] | [[Langerhans cell histiocytosis primary prevention|Primary Prevention]] | [[Langerhans cell histiocytosis secondary prevention|Secondary Prevention]] | [[Langerhans cell histiocytosis cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Langerhans cell histiocytosis future or investigational therapies|Future or Investigational Therapies]]
<br />Solitary bone lesion may be amenable through excision or limited radiation. However systemic disease often require chemotherapy.
<br />Use of systemic steroid is common, singly or adjunct to chemotherapy. Local steroid cream is applied to skin lesions.
<br />Endocrine deficiency often require lifelong suppliment e.g. desmopressin for diabates insipidus which can be applied as nasal drop.
<br />[[Chemotherapeutic]] agents such as [[alkylating antineoplastic agent|alkylating agents]], [[antimetabolite]]s, [[vinca alkaloids]] either singly or in combination can lead to complete remission in diffuse disease.


==Prognosis==
==Case Studies==
Excellent for single foci disease.
[[Langerhans cell histiocytosis case study one|Case #1]]
<br />With multi-focal disease 60% have a chronic course, 30% achieve remission and mortality is up to 10%<ref>{{cite journal |author=Komp D, El Mahdi A, Starling K, Easley J, Vietti T, Berry D, George S |title=Quality of survival in histiocytosis X: a Southwest Oncology Group study |journal=Med. Pediatr. Oncol. |volume=8 |issue=1 |pages=35-40 |year=1980 |pmid=6969347}}</ref>.


==References==
==Related chapters==
{{Reflist|2}}
 
==See also==
* [[Histiocyte]]
* [[Histiocyte]]
* [[Histiocytosis]]
* [[Histiocytosis]]
* [[Langerhans cell]]
* [[Langerhans cell]]


==External links==
==Resources==
*[http://youtube.com/watch?v=KkBRqZS8nfM Seven Part Video Series]
*[http://youtube.com/watch?v=KkBRqZS8nfM Seven Part Video Series]


{{SIB}}
{{Hematology}}
{{Hematology}}
{{Hematological malignancy histology}}
{{Hematological malignancy histology}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}


[[Category:Disease]]
[[Category:Disease]]
Line 116: Line 48:
[[Category:Oncology]]
[[Category:Oncology]]
[[Category:Hematology]]
[[Category:Hematology]]
[[Category:Mature chapter]]
[[Category:Types of cancer]]
 
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
[[Category:Up-To-Date]]
[[Category:Oncology]]
[[Category:Medicine]]
[[Category:Dermatology]]
[[Category:Surgery]]

Latest revision as of 02:09, 27 November 2017

For patient information, click here

Langerhans cell histiocytosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Langerhans cell histiocytosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Langerhans cell histiocytosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Langerhans cell histiocytosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Langerhans cell histiocytosis

on Langerhans cell histiocytosis

Langerhans cell histiocytosis in the news

Blogs on Langerhans cell histiocytosis

Directions to Hospitals Treating Langerhans cell histiocytosis

Risk calculators and risk factors for Langerhans cell histiocytosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief:

Synonyms and keywords: Histiocytosis X; Histiocytosis X syndrome; Hand-Schüller-Christian disease; Letterer-Siwe disease; Eosinophilic granulomatosis unspecified; Langerhans cell granulomatosis; Langerhans cell histiocytosis-Hashimoto-Pritzker type; Langerhans cell histiocytosis, disseminated (clinical); Langerhans cell histiocytosis, unifocal (clinical); Langerhans cell histiocytosis of the lung; Non-lipid reticuloendotheliosis; Eosinophilic granuoloma; Pulmonary histiocytosis X; Pulmonary Langerhans cell granulomatosis

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Langerhans cell histiocytosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History amd Symptoms | Physical Examination | Laboratory Findings | Electrocardiogram | Chest X Ray | CT | MRI | Echocardiography or Ultrasound | Other Imaging Findings | Other Diagnostic Studies

Treatment

Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies

Case Studies

Case #1

Related chapters

Resources

Template:Hematology


Template:WikiDoc Sources